CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash Flows from Operating Activities:
Net income	$ 31,713	$ 50,292
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	8,008	7,555
Non-cash compensation	7,347	7,307
Amortization and impairment of operating lease right of use assets	10,096	9,850
Loss on disposal of property and equipment	5	14
Deferred income taxes	3,205	7,411
Equity in loss (earnings) from equity method investments	1,403	(1,118)
Amortization of deferred debt issuance costs/debt discount	248	216
Return on equity method investments	1,710	1,500
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(18,618)	(20,448)
Other current assets	7,882	(2,874)
Other assets	247	(115)
Accounts payable	(2,115)	(3,374)
Accrued expenses	7,483	8,370
Other long-term obligations	(57)	(808)
Operating lease liabilities	(9,187)	(9,014)
Operating lease right of use assets	(749)	(762)
Net cash provided by operating activities	48,621	54,002
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets	22	19
Proceeds from the sale of property and equipment	37	42
Purchases of property and equipment	(902)	(1,618)
Investments in technology assets	(236)	0
Other investments	(15,000)	0
Net cash used in investing activities	(16,079)	(1,557)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options	86	364
Proceeds from issuance of stock to employee stock purchase plan	985	1,048
Shares withheld to pay taxes on non-cash compensation	(4,682)	(6,774)
Noncontrolling interest contributions	652	0
Noncontrolling interest distributions	(672)	(518)
Proceeds from borrowings under revolving line of credit	0	215,200
Repayments of borrowings under revolving line of credit	0	(186,200)
Principal payments of long-term obligations	(3,771)	(2,692)
Purchase of company stock	0	(72,886)
Provider relief fund advance	0	(5,000)
Net cash used in financing activities	(7,402)	(57,458)
Net increase (decrease) in cash, cash equivalents and restricted cash	25,140	(5,013)
Cash, cash equivalents and restricted cash at beginning of period	45,769	83,357
Cash, cash equivalents and restricted cash at end of period	70,909	78,344
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	1,864	1,011
Cash paid for income taxes, net of refunds received	551	971
Cash paid for operating lease liabilities	9,936	9,776
Cash paid for finance lease liabilities	357	503
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	11,203	10,548
Right of use assets obtained in exchange for finance lease liabilities	216	177
Reductions to right of use assets resulting from reductions to operating lease liabilities	299	279
Noncontrolling interest contribution	$ 8,900	$ 0